Page last updated: 2024-11-11

mulberroside a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mulberroside A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6443484
CHEMBL ID455619
CHEBI ID177974
SCHEMBL ID22498775
MeSH IDM0379477

Synonyms (29)

Synonym
102841-42-9
(2s,3r,4s,5s,6r)-2-[3-hydroxy-4-[(e)-2-[3-hydroxy-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
CHEBI:177974
mulberroside a
CHEMBL455619
S9075
n1520 ,
unii-oju5sva08b
oju5sva08b ,
CS-4679
[2,5'-dihydroxy-4,3'-bis(beta-d-glucopyranosyloxy)-trans-stilbene]
AC-34709
Q-100952
mulberroside-a
HY-N0619
AKOS030526209
3-((1e)-2-(4-(.beta.-d-glucopyranosyloxy)-2-hydroxyphenyl)ethenyl)-5-hydroxyphenyl .beta.-d-glucopyranoside
.beta.-d-glucopyranoside, 3-((1e)-2-(4-(.beta.-d-glucopyranosyloxy)-2-hydroxyphenyl)ethenyl)-5-hydroxyphenyl
mfcd16294844
(2s,3r,4s,5s,6r)-2-(3-hydroxy-4-((e)-3-hydroxy-5-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)styryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
Q6933784
CCG-270083
AS-56590
SCHEMBL22498775
bdbm50529592
A904166
3-{(e)-2-[4-(beta-d-glucopyranosyloxy)-2-hydroxyphenyl]ethenyl}-5-hydroxyphenyl beta-d-glucopyranoside
DTXSID901030445
mulberrosidea

Research Excerpts

Overview

Mulberroside A is a natural polyhydroxylated stilbene compound present at relatively high abundance in the roots and twigs of Morus alba L. It is a glycosylate of oxyresveratrol. deglycosylation of mulberro side A resulted in enhanced inhibition of melanogenesis.

ExcerptReferenceRelevance
"Mulberroside A is a natural polyhydroxylated stilbene compound present at relatively high abundance in the roots and twigs of Morus alba L. "( Mulberroside A protects against ischemic impairment in primary culture of rat cortical neurons after oxygen-glucose deprivation followed by reperfusion.
Ding, F; Li, GC; Li, JL; Liang, XM; Shi, YW; Wang, CP; Wang, ZW; Zhang, LZ; Zhang, XC, 2014
)
3.29
"Mulberroside A is a major stilbene glycoside of MORUS ALBA L. "( Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice.
Hu, LS; Kong, LD; Wang, CP; Wang, X; Wang, Y; Ye, JF; Zhang, X, 2011
)
3.25
"Mulberroside A is a glycosylated stilbene of oxyresveratrol; thus, the deglycosylation of mulberroside A resulted in enhanced inhibition of melanogenesis."( Inhibitory effect of mulberroside A and its derivatives on melanogenesis induced by ultraviolet B irradiation.
Hwang, D; Kim, JK; Lim, YH; Park, KT; Yoo, Y, 2011
)
1.41

Actions

ExcerptReferenceRelevance
"Mulberroside A was found to inhibit hippocampal neuroinflammation and neurogenesis reduction in HFrD-fed mice."( Mulberroside A repairs high fructose diet-induced damage of intestinal epithelial and blood-brain barriers in mice: A potential for preventing hippocampal neuroinflammatory injury.
Kong, L; Li, J; Wang, C; Wang, Q; Wen, S; Wu, X; Yu, R; Zhang, L, 2021
)
2.79

Pharmacokinetics

ExcerptReferenceRelevance
" This study examined the determining factors for previously reported oral pharmacokinetic profiles of MulA and its bacterial metabolite oxyresveratrol (OXY) on in vitro models."( In vitro pharmacokinetic characterization of mulberroside A, the main polyhydroxylated stilbene in mulberry (Morus alba L.), and its bacterial metabolite oxyresveratrol in traditional oral use.
Lei, JP; Mei, M; Ruan, JQ; Wang, YT; Wu, WJ; Yan, R; Zhao, HY; Zhou, RN, 2012
)
0.64

Dosage Studied

ExcerptRelevanceReference
"Potassium oxonate-induced hyperuricemic mice were dosed by gavage with eight stilbenes."( Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TyrosinaseMus musculus (house mouse)IC50 (µMol)100.00000.03002.21045.2300AID1611935
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID332856Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets
AID332852Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets
AID1611935Inhibition of tyrosinase in mouse B16 cells2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID332858Inhibition of thromboxane B2 formation in Wistar King platelets
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (11.11)29.6817
2010's22 (81.48)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.65 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]